Skip Navigation


Rheumatology Advance Access originally published online on December 16, 2003
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
43/4/472    most recent
keh070v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sultan, N.
Right arrow Articles by Clements, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sultan, N.
Right arrow Articles by Clements, P. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2004; 43: 472-478
Rheumatology Vol. 43 No. 4 (c) British Society for Rheumatology 2004; all rights reserved

Clinical

The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma

N. Sultan, J. E. Pope and P. J. Clements1 for the Scleroderma Trials Study Group*

Department of Medicine, The University of Western Ontario, Canada and 1UCLA School of Medicine, Los Angeles, California, USA.

Correspondence to: J. E. Pope, Rheumatology Centre, St. Joseph's Health Care London, 268 Grosvenor Street, Box 5777, London ON N6A 4V2, Canada. E-mail: janet.pope{at}sjhc.london.on.ca

Objective. Scoring poorly on the health assessment questionnaire (HAQ) has recently been shown to be a strong predictor of morbidity and mortality in rheumatoid arthritis (RA), while a good HAQ score is predictive of a better outcome. In patients presenting with early diffuse scleroderma prognosis is variable. Our goal was to determine possible baseline predictors of future good outcomes.

Methods. We used the raw data from two randomized controlled trials (RCTs) in early diffuse scleroderma: methotrexate (Pope et al.) and D-penicillamine (Clements et al.). Subjects in the methotrexate trial were divided into the following groups: (1) those with at least 20% improvement in the primary outcome measurements [patient global assessment, physician global assessment, UCLA skin tethering score, modified Rodnan skin score (MRSS), DLCO as % predicted and HAQ disability] at 1 yr vs (2) the others. Baseline factors (including age, gender, skin scores, physician and patient global assessments, HAQ disability and pain scores, DLCO and physical parameters) were analysed to find baseline variables strongly correlated with later improvement. These variables were explored in the D-penicillamine trial to determine if (in a separate trial) they were still predictive of improved outcome at 1 and 2 yr. Adjusted models were used to find baseline predictors of good outcome. The median HAQ-DI was 1.3 (methotrexate) and 1.0 (D-penicillamine).

Results. A baseline HAQ disability score of less than the median was predictive of at least a 20% improvement at 1 and 2 yr with odds ratios of 1.77 to 5.05, in four of the five outcome measurements (in both groups); with strongly significant P values for 3 of 5 outcomes (UCLA skin score, MRSS, patient global skin score; P<0.02) from the methotrexate study group. These three outcomes were strongly correlated with improvement (r between 0.25 and 0.35). Although data from the D-penicillamine trial were less convincing, in both trials the less than median HAQ-DI and HAQ pain scores showed a stronger association with improved outcome, more so than age, gender, skin score and baseline global assessment.

Conclusion. A low baseline HAQ (defined as less than the median HAQ score) is predictive of improved outcome in diffuse scleroderma at 1 and 2 yr.

KEY WORDS: Early diffuse scleroderma, HAQ, Prognosis, Good outcome.

*The Scleroderma Trials Study Group: D. E. Furst, J. R. Siebold, W. K. Wong, N. Bellamy, M. Mayes, M. Baron, B. White, M. Ellman, F. Wigley, S. Carette, M. H. Weisman, C. D. Smith, W. Barr, I. M. Chalmers, L. W. Moreland, T. A. Medsger Jr, P. Hong, V. Steen, D. O’Hanlon, R. W. Martin, E. Kaminska, D. Collier, J. Markland, E. Lally, J. Sibley, J. Varga, L. Catoggio, S. Weiner, B. Andrews and M. Abeles.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann Rheum DisHome page
L. Czirjak, Z. Nagy, M. Aringer, G. Riemekasten, M. Matucci-Cerinic, D. E Furst, and on behalf of EUSTAR
The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis
Ann Rheum Dis, July 1, 2007; 66(7): 966 - 969.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
S. R. Johnson and P. Lee
The HAQ disability index in scleroderma trials
Rheumatology, September 1, 2004; 43(9): 1200 - 1201.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.